Blood Plasma of Patients with Parkinson’s Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity

Table 1

Population characteristics of control group and PD patient group.

	Age, yr	Gender, F/M	PD duration, yr	LEDD, mg	MoCA, mean ± SD (range)	UPDRS III	BDI
CTL,	55.41 ± 10.23	9/19	—	—	26.5 ± 1.4 (25–30)	—	6 ± 3
PD,	56.68 ± 11.42	9/19	4.88 ± 3.6	506.25 ± 260.45	25.8 ± 1.6 (24–30)	33.25 ± 12.14	7 ± 3

M = male; F = female; PD = Parkinson disease patients; LEDD = meanL-dopaequivalent daily dose; MoCA = Montreal Cognitive Assessment; UPDRS III = Unified Parkinson Disease Rating Scale, part III (motor); BDI = Beck Depression Inventory.